Comparison of sevelamer hydrochloride and sevelamer carbonate: Risk of metabolic acidosis and clinical implications

Pharmacotherapy

Volumn 29, Issue 5, 2009, Pages 554-561

  Pai, Ashwini B ^a   Shepler, Brian M ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Chronic kidney disease; Hyperphosphatemia; Metabolic acidosis; Sevelamer carbonate; Sevelamer hydrochloride

Indexed keywords

BICARBONATE; CALCIUM ACETATE; CALCIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSTIPATION; DRUG ABSORPTION; DRUG BINDING; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MEDLINE; METABOLIC ACIDOSIS; NAUSEA; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; VOMITING;

ACIDOSIS; ANIMALS; BICARBONATES; CHELATING AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERPHOSPHATEMIA; ION EXCHANGE RESINS; KIDNEY FAILURE, CHRONIC; POLYAMINES; RISK FACTORS;

EID: 66249108582     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.5.554     Document Type: Review

References (36)

1. Hruska K, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int 2008;74(2):148-57.
2. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003;26:1093-115.
3. Mathew S, Lund R, Strebeck F, Tustison K, Geurs T, Hruska K. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007;18:122-30.
4. Davis MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-9.
5. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal diseases: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40.
6. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
7. Goodman WG, Goldin J, Kuizon BD, et al. Coronary artery calcification in young adults with end stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(4 suppl 3):1-201.
9. Braun J, Asmus HG, Holzer H, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate:phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-15.
10. Qunibi W, Hootkins R, McDowell L, et al. Treatment of hyperphosphatemia in hemodialysis patients: the calcium acetate Renagel evaluation (CARE study). Kidney Int 2004;65:1914-26.
11. Sprague S. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer and lanthanum carbonate. Curr Med Res Opin 2007;23:3167-75.
12. Harrison T, Scott L. Lanthanum carbonate. Drugs 2004;64(9):985-96.
13. Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binder lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci 2007;96:2818-27.
14. Genzyme Corporation. Renagel (sevelamer hydrochloride) package insert. Cambridge, MA; 2007.
15. Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli ST, Vlassopoulos DA. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-7.
16. Vlahakos D, Retsa K, Kalogeropoulou S, Katsoudas S, Bacharaki D, Agroyannis B. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. Artif Organs 2007;31(12):892-5.
17. De Santo N, Frangiosa A, Anastasio P, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006;19(suppl 9):S108-14.
18. Oka Y, Miyazaki M, Takatsu S, et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11(2):107-13.
19. Genzyme Corporation. Renvela (sevelamer carbonate) package insert. Cambridge, MA; 2007.
20. Wrong, O, Harland C. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 2007;107:17-33.
21. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer hydrochloride. Kidney Int 2002;62(2):611-19.
22. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Neph 1998;50(6):381-6.
23. Ramos R, Moreso F, Borras M, et al. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter crosssectional study. Perit Dial Int 2007;27:697-701.
24. Kasimatis E, Maksich D, Jassal V, Bargman JM, Oreopoulos D. Predictive factors of low HCO3 levels in peritoneal dialysis patients. Clin Nephrol 2005;63(4):290-6.
25. Fourtounas C, Savidaki E, Roumelioti M, et al. Acid-base profile and predictors of metabolic acidosis in patients undergoing peritoneal dialysis with lactate- and bicarbonatebuffered peritoneal dialysis solutions. Adv Perit Dial 2006;22:187-91.
26. Page D, Knoll G. Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. Adv Perit Dial 2005;21:185-7.
27. Duggal A, Hanus M, Zhorov E, et al. Novel dosage forms and regimens for sevelamer based phosphate binders. J Ren Nutr 2006;16(3):248-52.
28. Delmez J, Block G, Robertson J, et al. A randomized, doubleblind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91.
29. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008;3(4):1125-30.
30. Thompson Healthcare. Drug topics red book. Montvale, NJ;2008.
31. Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004;13(1):134-41.
32. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149(5):820-5.
33. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19(6):1489-96.
34. Sonikian M, Metaxaki P, Iliopoulos A, Marioli S, Vlassopoulos D. Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. Ren Fail 2006;28:411-18. (Erratum in Ren Fail 2007;29(1):119.)
35. Reuters. Genzyme cites mixed results for Renvela powder. June 18, 2007. Available from www.reuters.com/article/ company NewsAndPR/idUSN1838690120070618. Accessed August 11, 2008.
36. Medical News Today. Genzyme announces results of clinical trials investigating powder form of sevelamer carbonate. June 19, 2007. Available from www.medicalnewstoday.com/articles/74584.php. Accessed August 11, 2008.